A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

• Type of Material: Article
• Authors: Lisa H. Butterfield, University of Pittsburgh; Mary L. Disis, University of Washington; Bernard A. Fox, Providence Portland Medical Center; Peter P. Lee, Stanford University; Samir N. Khleif, National Cancer Institute; Magdalena Thurin, National Cancer Institute; Giorgio Trinchieri, National Cancer Institute; Ena Wang, National Institutes of Health; Jon Wigginton, Bristol Myers Squibb Co; Damien Chaussabel, Baylor Institute for Immunology Research; George Coukos, University of Pennsylvania; Madhav Dhodapkar, Emory University; Leif Hakansson, Lund University; Sylvia Janetzki, ZellNet Consulting Inc; Thomas O. Kleen, Cellular Technololgy Ltd; John M. Kirkwood, University of Pittsburgh; Cristina Maccalli, Istitute of Science San Raffaele; Holden Maecker, Baylor Institute for Immunology Research; Michele Maio, University Hospital of Siena; Anatoli Malyguine, National Cancer Institute; Giuseppe Masucci, Karolinska Institutet; A. Karolina Palucka, Baylor Institute for Immunology Research; Douglas M. Potter, University of Pittsburgh; Antoni Ribas, University of California Los Angeles; Licia Rivoltini, Istituto Nazionale Tumori IRCCS; Dolores Schendel, German Research Center for Environmental Health; Barbara Seliger, University of Halle Wittenberg; Senthamil Selvan, Hoag Cancer Center; Craig L. Slingluff Jr., University of Virginia; David F. Stroncek, National Institutes of Health; Howard Streicher, National Cancer Institute; Xifeng Wu, University of Texas Houston; Benjamin Zeskind, Immuneering Corp; Yingdong Zhao, National Cancer Institute; Mai-Britt Zocca, DanDritt Biotech AS; Heinz Zwierzina, Innsbruck Medical University; Francesco M. Marincola, National Institutes of Health
• Language: English
• Date: 2008-12-23
• Publisher: BMC
• Publication Version: Final Published Version
• Copyright Statement: © 2008 Butterfield et al; licensee BioMed Central Ltd.
• License: Creative Commons Attribution 2.0 Generic
• Final Published Version (URL): http://dx.doi.org/10.1186/1479-5876-6-81
• Title of Journal or Parent Work: Journal of Translational Medicine
• ISSN: 1479-5876
• Volume: 6
• Issue: 1
• Start Page: 81
• End Page: 81
• Keywords: Research & Experimental Medicine; EXPRESSION ANALYSIS; TETRAMER; ELISPOT; CYTOKINE FLOW-CYTOMETRY; CELLS; THERAPY; INTERLEUKIN-2; CANCER; Life Sciences & Biomedicine; Medicine, Research & Experimental; MELANOMA; CRYOPRESERVATION; Science & Technology
• Research Categories: Health Sciences, Immunology; Health Sciences, Oncology

Abstract

The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.